• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The journal of clinical psychiatry >A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder.
【24h】

A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder.

机译：氟西汀，奥氮平和奥氮平-氟西汀组合在边缘性人格障碍女性中的初步随机试验。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: The intent of this study was to compare the efficacy and safety of fluoxetine, olanzapine, or the olanzapine-fluoxetine combination (OFC) in the treatment of women meeting criteria for borderline personality disorder (without concurrent major depressive disorder). METHOD: We conducted a randomized double-blind study of these agents in female subjects meeting Revised Diagnostic Interview for Borderlines (DIB-R) and DSM-IV criteria for borderline personality disorder. Treatment duration was 8 weeks. Outcome measures were clinician-rated scales measuring depression (the Montgomery-Asberg Depression Rating Scale) and impulsive aggression (the Modified Overt Aggression Scale). Data were collected from August 2001 through March 2003. RESULTS: Fourteen subjects were randomized to fluoxetine; 16, to olanzapine; and 15, to OFC. Forty-two of these subjects (93.3%) completed all 8 weeks of the trial. Using random-effects regression modeling of panel data of change-from-baseline scores and controlling for time, olanzapine monotherapy and OFC were associated with a significantly greater rate of improvement over time than fluoxetine on both outcome measures. However, it should be noted that fluoxetine treatment led to a substantial reduction in impulsive aggression and severity of depression. Weight gain was relatively modest in all 3 groups but significantly greater in the olanzapine-treated group than in the groups treated with fluoxetine alone or OFC. CONCLUSION: All 3 compounds studied appear to be safe and effective agents in the treatment of women with borderline personality disorder, significantly ameliorating the chronic dysphoria and impulsive aggression common among borderline patients. However, olanzapine monotherapy and OFC seem to be superior to fluoxetine monotherapy in treating both of these dimensions of borderline psychopathology.
机译：背景：本研究的目的是比较氟西汀，奥氮平或奥氮平-氟西汀组合（OFC）在治疗符合边缘型人格障碍（无并发严重抑郁症）标准的女性中的疗效和安全性。方法：我们对女性受试者进行了针对这些药物的随机双盲研究，这些受试者符合针对边缘性人格障碍的修订诊断性边界访谈（DIB-R）和DSM-IV标准。治疗时间为8周。结果指标是临床医生评定的抑郁量表（蒙哥马利-阿斯伯格抑郁量表）和冲动攻击量（改良的公开攻击量表）。结果：从2001年8月到2003年3月收集了数据。结果：14名受试者被随机分配使用氟西汀。 16，去奥氮平;和15，到OFC。这些受试者中有42位（93.3％）完成了试验的所有8周。使用从基线变化得分的面板数据的随机效应回归模型并控制时间，奥氮平单药和OFC随时间的改善率在两个结局指标上均显着高于氟西汀。然而，应该指出的是，氟西汀治疗导致冲动攻击和抑郁严重程度的显着降低。在所有三个组中，体重增加相对较小，但在奥氮平治疗组中，其体重增加显着大于单独使用氟西汀或OFC治疗的组。结论：所研究的所有三种化合物似乎是治疗边缘性人格障碍妇女的安全有效药物，可显着缓解边缘性患者常见的慢性烦躁和冲动性攻击。然而，奥氮平单一疗法和OFC似乎在治疗边缘性心理病理学的这两个方面都优于氟西汀单一疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号